मूलभूत आँकड़े
| LEI | 549300DNCEGUZLZ8SP61 |
| CIK | 1493566 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Otonomy Inc
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| April 4, 2023 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTION 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-36591 Otonomy, Inc. (Exact name of registrant as specified in its |
|
| March 30, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. |
|
| March 30, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. |
|
| March 30, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. |
|
| March 30, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. |
|
| March 30, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. |
|
| March 30, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 POS AM As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 30, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. |
|
| March 30, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 S-8 POS 1 d474350ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. 333-263110 333-253000 333-236716 333-230055 333-223522 333-216401 333-209990 333-202851 333-198116 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 Post-Effective Amendment No. 1 to Registration Statement No. 333-263110 Post-Effective Amendment |
|
| March 30, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. |
|
| March 30, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. |
|
| March 30, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 POS AM As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. |
|
| March 30, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 POS AM As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 28, 2023 |
PLAN OF LIQUIDATION AND DISSOLUTION OTONOMY, INC. EX-99.1 Exhibit 99.1 PLAN OF LIQUIDATION AND DISSOLUTION OF OTONOMY, INC. The following Plan of Liquidation and Dissolution (the “Plan of Dissolution”), dated as of December 13, 2022, shall effect the dissolution and complete liquidation of Otonomy, Inc., a Delaware corporation (the “Company”), in accordance with Section 275 and other applicable provisions of the Delaware General Corporation Law ( |
|
| March 28, 2023 |
EX-4.1 Exhibit 4.1 CERTIFICATE OF DISSOLUTION OF OTONOMY, INC. Pursuant to Section 275 of the General Corporation Law of the State of Delaware Otonomy, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Otonomy, Inc. 2. The dissolution of the Corporation has been d |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 14, 2023 |
SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A, AMENDMENT #1 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Otonomy, Inc. (Title of Class of |
|
| February 13, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| February 13, 2023 |
OTIC / Otonomy Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d884301413g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Otonomy, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 68906L105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 10, 2023 |
OTIC / Otonomy Inc / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 9, 2023 |
OTIC / Otonomy Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - OTONOMY, INC. Passive Investment SC 13G/A 1 p23-0710sc13ga.htm OTONOMY, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Otonomy, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 68906L105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriat |
|
| January 30, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2023 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Num |
|
| December 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2022 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 29, 2022 |
Lease Termination Agreement, dated December 23, 2022 EX-10.1 Exhibit 10.1 LEASE TERMINATION AGREEMENT This Lease Termination Agreement (this “Agreement”) is executed as of December 23, 2022, between ARE-SD REGION NO. 34, LLC, a Delaware limited liability company (“Landlord”), and OTONOMY, INC., a Delaware corporation (“Tenant”), for the purpose of terminating the Lease Agreement between Landlord and Tenant dated May 11, 2015 (the “Lease”). Capitaliz |
|
| December 27, 2022 |
OTIC / Otonomy Inc / Elk Capital Markets UK LTD - THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Otonomy, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 68906L105 (CUSIP Number) NEEL PATEL elk capital m |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2022 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 19, 2022 |
Plan of Liquidation and Dissolution of Otonomy, Inc. EX-2.1 Exhibit 2.1 PLAN OF LIQUIDATION AND DISSOLUTION OF OTONOMY, INC. The following Plan of Liquidation and Dissolution (the “Plan of Dissolution”), dated as of December 13, 2022, shall effect the dissolution and complete liquidation of Otonomy, Inc., a Delaware corporation (the “Company”), in accordance with Section 275 and other applicable provisions of the Delaware General Corporation Law (th |
|
| December 19, 2022 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission |
|
| December 19, 2022 |
Otonomy Provides Corporate Update EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Provides Corporate Update SAN DIEGO, December 19, 2022 — Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution (“Plan of Dissolution”) that would include the distribution of remaining cash to stockholders following an o |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 14, 2022 |
OTIC / Otonomy Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* OTONOMY, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 68906L105 (CUSIP Number) November 14, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| November 10, 2022 |
OTIC / Otonomy Inc / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 10, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update Evaluation of strategic options to realize value from pipeline is ongoing SAN DIEGO, November 10, 2022 - Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quart |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36591 Otonomy, Inc. |
|
| October 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2022 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Num |
|
| September 16, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2022 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 9, 2022 |
OTIC / Otonomy Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6*) OTONOMY, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 68906L105 (CUSIP Number) August 31, 2022 (Date of Event Which Requires Filing of this Statement |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 03, 2022 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 2, 2022 |
OTIC / Otonomy Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) Otonomy, Inc. (Title of Class of Securities) Common Stock, Par Value $0.001 Per Share |
|
| August 2, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| August 1, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2022 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 1, 2022 |
Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus ? OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepoints ? Company to discontinue development of OTO-313 and implement other measures to extend its cash runway ? Clinical focus shifts to OTO-413 follo |
|
| July 25, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2022 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36591 Otonomy, Inc. (Exac |
|
| July 25, 2022 |
Outside Director Compensation Policy. Exhibit 10.1 OTONOMY, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Adopted and approved July 2, 2014 and effective as of the Company?s initial public offering Amended by the Board of Directors on April 28, 2015, and further amended on February 7, 2018, March 24, 2020 and April 12, 2022 Otonomy, Inc. (the ?Company?) believes that the granting of equity and cash compensation to its members of the Board |
|
| July 25, 2022 |
Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update ? Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line results expected in third quarter of 2022 ? Positive top-line results announced for |
|
| June 23, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 9, 2022 |
Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update ? Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluation ? OTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected in August 2022; clinical safety evaluation of higher and bilateral dosing ongo |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36591 Otonomy, Inc. (Exa |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2022 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 22, 2022 |
OTIC / Otonomy Inc / Weber David Allen - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Otonomy, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 68906L105 (CUSIP Number) April 16, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| April 20, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss ? Clinical benefit again observed for OTO-413 versus placebo for multiple efficacy endpoints based on responder analysis at both Days 57 and 85 ? Results support clinical activity and tolerability findings from previous Phase 1/2 trial ? Enrollment in h |
|
| April 20, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 20, 2022 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Number |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 28, 2022 |
Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update ? OTO-313 Phase 2 trial in tinnitus fully enrolled ahead of schedule with top-line results expected in mid-2022; initiating safety evaluation of higher and bilateral dosing ? OTO-413 Phase 2a cohort in hearing loss fully enrolled with top-line results expected early |
|
| February 28, 2022 |
Executive Employment Agreement between the Registrant and Paul E. Cayer. Exhibit 10.1 OTONOMY, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is entered into by and between Otonomy, Inc. (the ?Company?), and Paul E. Cayer (?Executive?) as of the date the Company and Executive have each executed this Agreement, as set forth below. The terms of this Agreement will become effective on April 16, 2021 (the ?Effective Date?). 1. Duties and Sc |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-36591 Otonomy, Inc. ( |
|
| February 28, 2022 |
As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. |
|
| February 28, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) OTONOMY, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per |
|
| February 28, 2022 |
Executive Employment Agreement between the Registrant and Robert Michael Savel, II. Exhibit 10.2 OTONOMY, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is entered into by and between Otonomy, Inc. (the ?Company?), and Robert Michael Savel, II (?Executive?) as of the date the Company and Executive have each executed this Agreement, as set forth below. The terms of this Agreement will become effective on April 16, 2021 (the ?Effective Date?). 1. Du |
|
| February 14, 2022 |
OTIC / Otonomy Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Otonomy, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 68906L105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 14, 2022 |
OTIC / Otonomy Inc / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Otonomy, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68906L05 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 14, 2022 |
OTIC / Otonomy Inc / Sofinnova Investments, Inc. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Otonomy, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68906L105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statemen |
|
| February 14, 2022 |
OTIC / Otonomy Inc / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
OTIC / Otonomy Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5*) OTONOMY, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 68906L105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Stateme |
|
| February 11, 2022 |
CUSIP No. 68906L105 SCHEDULE 13G Page 8 of 8 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 11, 2022 (the ?Schedule 13G?), with respect to the Ordinary Share $0.001 Par Value, of Otonomy, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange A |
|
| February 11, 2022 |
OTIC / Otonomy Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2022 |
OTIC / Otonomy Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No. |
|
| February 10, 2022 |
OTIC / Otonomy Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - OTONOMY, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Otonomy, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 68906L105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| January 6, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Corporate and Product Pipeline Update Multiple clinical trial readouts for OTO-313 in tinnitus and OTO-413 in hearing loss expected during 2022 Current capital funds operations into second half of 2023 SAN DIEGO, January 6, 2022 - Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for |
|
| January 6, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 06, 2022 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36591 Otonomy, Inc. (E |
|
| November 10, 2021 |
Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update ? OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022 ? Enrollment nearly complete in OTO-413 Phase 2a cohort in hearing loss with results moved forward to early in second quarter of 2022 ? Initiating clinical safety evaluation of higher dosing for OTO-413 t |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 25, 2021 |
OTIC / Otonomy Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Otonomy, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 68906L105 (CUSIP Number) October 13, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| August 19, 2021 |
Otonomy Appoints Jill Broadfoot to Board of Directors Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Appoints Jill Broadfoot to Board of Directors SAN DIEGO, August 19, 2021 ? Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the appointment of Jill Broadfoot to its board of directors. ?Jill is an excellent addition to the board with strong strategic, operati |
|
| August 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2021 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 18, 2021 |
Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-258465 PROSPECTUS SUPPLEMENT (To prospectus dated August 18, 2021) $40,000,000 Otonomy, Inc. Common Stock We have entered into a certain Common Stock Sales Agreement, or sales agreement, with Cowen and Company, LLC, or Cowen, relating to shares of our common stock offered by this prospectus supplement. In accordance with the t |
|
| August 16, 2021 |
August 16, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Ansart Re: Otonomy, Inc. Registration Statement on Form S-3 File No. 333-258465 Acceleration Request Requested Date: August 18, 2021 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 un |
|
| August 4, 2021 |
Exhibit 4.4 OTONOMY, INC. TO AS TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.1 Definitions. 1 Section 1.2 Compliance Certificates and Opinions. 9 Section 1.3 Form of Documents Delivered to Trustee. 9 Section 1.4 Acts of Holders; Record Dates. 10 Section 1.5 Notices, etc., to Trus |
|
| August 4, 2021 |
Executive Employment Agreement between the Registrant and Alan C. Foster, Ph.D. Exhibit 10.2 OTONOMY, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is entered into by and between Otonomy, Inc. (the ?Company?), and Alan C. Foster, Ph.D. (?Executive?) as of the date the Company and Executive have each executed this Agreement, as set forth below. The terms of this Agreement will become effective on April 16, 2021 (the ?Effective Date?). 1.Duties |
|
| August 4, 2021 |
Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update ? OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022 ? OTO-413 Phase 1/2 trial expansion in hearing loss ongoing with results expected in mid-2022 ? OTO-825 preclinical proof-of-concept results presented at ASGCT meeting; Pre-IND meeting complete and IND-e |
|
| August 4, 2021 |
Exhibit 4.2 OTONOMY, INC. TO AS TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.1 Definitions. 1 Section 1.2 Compliance Certificates and Opinions. 7 Section 1.3 Form of Documents Delivered to Trustee. 8 Section 1.4 Acts of Holders; Record Dates. 9 Section 1.5 Notices, etc., to Trustee and |
|
| August 4, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 Otonomy, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 4, 2021 |
As filed with the Securities and Exchange Commission on August 4, 2021 Table of Contents As filed with the Securities and Exchange Commission on August 4, 2021 Registration No. |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36591 Otonomy, Inc. (Exact |
|
| August 4, 2021 |
Sales Agreement, dated as of August 4, 2021, between the Registrant and Cowen and Company, LLC. Exhibit 1.2 OTONOMY, INC. $40,000,000 COMMON STOCK SALES AGREEMENT August 4, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Otonomy, Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement, |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 4, 2021 |
Sales Agreement, dated as of August 4, 2021, between the Registrant and Cowen and Company, LLC. EX-1.1 2 d214176dex11.htm EX-1.1 Exhibit 1.1 OTONOMY, INC. $40,000,000 COMMON STOCK SALES AGREEMENT August 4, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Otonomy, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time d |
|
| August 4, 2021 |
Exhibit 10.1 Third Amendment TO LOAN AND SECURITY AGREEMENT This Third Amendment to Loan and Security Agreement (this ?Amendment?) is entered into as of June 2, 2021, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (in such capacity, ?Collateral Agent?), the |
|
| June 24, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2021 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2021 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 11, 2021 |
Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update ? OTO-313 Phase 2 trial in tinnitus initiated with results expected in mid-2022 ? OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021 with results anticipated in mid-2022 ? OTO-825 IND-enabling activities underway with preclinical proof-of- |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36591 Otonomy, Inc. (Exact |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 22, 2021 |
SC 13G 1 p21-1218sc13g.htm ADAGE CAPITAL PARTNERS GP, L.L.C. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Otonomy, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 68906L105 (CUSIP Number) April 12, 2021 (Date of Event Which Requires Filing of This Statement) Check the |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 12, 2021 |
SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 12, 2021 |
Exhibit 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Otonomy, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. April 12, 2021 BAKER BROS. ADVISORS LP By: Baker Bros. Advisors (GP) LLC, its general par |
|
| April 9, 2021 |
Otonomy Announces Proposed Public Offering EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Announces Proposed Public Offering SAN DIEGO, April 7, 2021 - Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be off |
|
| April 9, 2021 |
Underwriting Agreement, dated as of April 7, 2021, among Otonomy, Inc. and the representatives Exhibit 1.1 OTONOMY, INC. 6,288,890 Shares of Common Stock And Pre-Funded Warrants to Purchase 7,111,110 Common Shares Underwriting Agreement April 7, 2021 COWEN AND COMPANY, LLC PIPER SANDLER & CO. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Cowen and Company, LLC 599 Lexington Avenue, 27th Floor New York, New York 10022 c/o Piper Sandler & Co. 345 Park Avenue N |
|
| April 9, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 7, 2021 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 9, 2021 |
6,288,890 Shares of Common Stock Pre-Funded Warrants to Purchase 7,111,110 Shares of Common Stock 424B5 1 d140934d424b5.htm 424B5 Table of Contents As filed pursuant to Rule 424(b)(5) Registration No. 333-227269 Prospectus supplement (To prospectus dated September 21, 2018) 6,288,890 Shares of Common Stock Pre-Funded Warrants to Purchase 7,111,110 Shares of Common Stock We are offering 6,288,890 shares of our common stock and, in lieu of common stock to certain investors that so choose, pre-fu |
|
| April 9, 2021 |
Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Original Issue Date: [ ], 2021 Otonomy, Inc. , a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the ?Holder?), is entitled, subject to the terms s |
|
| April 9, 2021 |
Otonomy Announces Pricing of $30.1 Million Public Offering EX-99.2 Exhibit 99.2 FOR IMMEDIATE RELEASE Otonomy Announces Pricing of $30.1 Million Public Offering SAN DIEGO, April 7, 2021 — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pricing of an underwritten public offering of 6,288,890 shares of its common stock at a price to the public of $2.25 per |
|
| April 7, 2021 |
Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock 424B5 1 d140934d424b5.htm 424B5 Table of Contents As filed pursuant to Rule 424(b)(5) Registration No. 333-227269 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus s |
|
| February 22, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 22, 2021 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 22, 2021 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière’s Disease SAN DIEGO, February 22, 2021 — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the Phase 3 clinical trial of OTIVIDEX in patients with Méni |
|
| February 16, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* Otonomy, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68906L105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement |
|
| February 16, 2021 |
SC 13G/A 1 d121695dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Otonomy, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 68906L 105 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 16, 2021 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Otonomy, Inc. (Title of Class of Securities) Common Stock, Par Value $0.001 Per Share |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Otonomy, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68906L05 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Otonomy, Inc. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Otonomy, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Titles of Class of Securities) 68906L105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 12, 2021 |
CUSIP No. 68906L105 SCHEDULE 13G Page 8 of 8 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 12, 2021 (the “Schedule 13G”), with respect to the Common Stock, par value $0.0001 per share, of Otonomy, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-36591 Otonomy, Inc. ( |
|
| February 11, 2021 |
Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update • OTIVIDEX® Phase 3 trial results in Ménière’s disease expected by end of February • OTO-313 Phase 2 trial in tinnitus planned to start in first quarter of 2021 with top-line results expected in mid-2022 • OTO-413 Phase 1/2 trial expansion in hearing loss expected to |
|
| February 11, 2021 |
As filed with the Securities and Exchange Commission on February 11, 2021 Registration No. |
|
| February 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2021 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 10, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3*) OTONOMY, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 68906L105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Stateme |
|
| February 10, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4*) OTONOMY, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 68906L105 (CUSIP Number) January 31, 2021 (Date of Event Which Requires Filing of this Statemen |
|
| November 4, 2020 |
Otonomy Reports Third Quarter 2020 Financial Results and Provides Corporate Update Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Third Quarter 2020 Financial Results and Provides Corporate Update • Enrollment completed in Phase 3 clinical trial of OTIVIDEX® in Ménière’s disease with results expected in the first quarter of 2021 • Positive results reported for Phase 1/2 clinical trial of OTO-313 in tinnitus patients • Enrollment completed in Phase 1/2 clinical trial of OTO-4 |
|
| November 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36591 Otonomy, Inc. (E |
|
| August 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36591 Otonomy, Inc. (Exact |
|
| August 4, 2020 |
Otonomy Reports Second Quarter 2020 Financial Results and Provides Corporate Update Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Second Quarter 2020 Financial Results and Provides Corporate Update • Positive top-line results reported for Phase 1/2 trial of OTO-313 in tinnitus patients • Public offering completed for total gross proceeds of $69.1 million • Results from Phase 3 trial of OTIVIDEX® in Ménière’s disease expected in first quarter of 2021 • Results from Phase 1/2 |
|
| July 20, 2020 |
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of July 20, 2020, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/o |
|
| July 20, 2020 |
OTIC / Otonomy, Inc. / Cormorant Asset Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Otonomy, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68906L05 (CUSIP Number) July 10, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| July 14, 2020 |
OTIC / Otonomy, Inc. / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) Otonomy, Inc. (Title of Class of Securities) Common Stock, Par Value $0.001 Per Share |
|
| July 14, 2020 |
EX-99.1 2 p36321666b.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behal |
|
| July 10, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 9, 2020 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 10, 2020 |
14,500,000 Shares of Common Stock Pre-Funded Warrants to Purchase 4,000,000 Shares of Common Stock 424B5 Table of Contents As filed pursuant to Rule 424(b)(5) Registration No. 333-227269 Prospectus supplement (To prospectus dated September 21, 2018) 14,500,000 Shares of Common Stock Pre-Funded Warrants to Purchase 4,000,000 Shares of Common Stock We are offering 14,500,000 shares of our common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchas |
|
| July 10, 2020 |
EX-4.1 Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Original Issue Date: [ ], 2020 Otonomy, Inc. , a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder”), is entitled, subject to the |
|
| July 10, 2020 |
Otonomy Announces Pricing of $60.1 Million Public Offering EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Announces Pricing of $60.1 Million Public Offering SAN DIEGO, July 9, 2020 — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pricing of an underwritten public offering of 14,500,000 shares of its common stock at a price to the public of $3.25 per |
|
| July 10, 2020 |
Underwriting Agreement, dated as of July 9, 2020, among Otonomy, Inc. and the Underwriters EX-1.1 Exhibit 1.1 OTONOMY, INC. 14,500,000 Shares of Common Stock And Pre-Funded Warrants to Purchase 4,000,000 Common Shares Underwriting Agreement July 9, 2020 COWEN AND COMPANY, LLC PIPER SANDLER & CO. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Cowen and Company, LLC 599 Lexington Avenue, 27th Floor New York, New York 10022 c/o Piper Sandler & Co. 800 Nicoll |
|
| July 9, 2020 |
Otonomy Announces Proposed Public Offering EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Announces Proposed Public Offering SAN DIEGO, July 8, 2020 - Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offe |
|
| July 9, 2020 |
Amended and Restated Bylaws of the Registrant. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF OTONOMY, INC. (as amended and restated on July 7, 2020) TABLE OF CONTENTS Page ARTICLE I — CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II — MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 1 2.5 NOTICE OF STOCKHOLDERS’ MEETINGS 4 2.6 QUORUM 4 2.7 |
|
| July 9, 2020 |
Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock 424B5 Table of Contents As filed pursuant to Rule 424(b)(5) Registration No. 333-227269 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompan |
|
| July 9, 2020 |
EX-99.2 Exhibit 99.2 RISK FACTORS An investment in our securities involves a high degree of risk. Prior to making a decision about investing in our securities, you should carefully consider the specific factors discussed below and discussed under the section entitled “Risk Factors” contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and our Quarterly Report on F |
|
| July 9, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 7, 2020 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 6, 2020 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus • OTO-313 demonstrated a higher proportion of responders than placebo • Given clear signal in this proof of concept study, Otonomy plans to advance OTO-313 to full Phase 2 development in tinnitus • OTO-313 was well-tolerated with lower incidence of |
|
| July 6, 2020 |
EX-99.2 Exhibit 99.2 FOR IMMEDIATE RELEASE Otonomy Provides Update on OTIVIDEX® Program Management will review the OTIVIDEX statistical analysis plan update together with the positive top-line OTO-313 Phase 1/2 trial results during a conference call today at 4:30 p.m. ET SAN DIEGO, July 6, 2020 — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative t |
|
| July 6, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2020 Otonomy, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 26, 2020 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2020 Otonomy, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 10, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36591 Otonomy, Inc. (Exact |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 7, 2020 |
Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update Conference call to review status of clinical trials and timing to results to be held in June SAN DIEGO, May 7, 2020 - Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results |
|
| April 27, 2020 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 9, 2020 |
Otonomy Provides Business Update Related to COVID-19 Pandemic Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Provides Business Update Related to COVID-19 Pandemic SAN DIEGO, April 9, 2020 - Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a business update related to the COVID-19 pandemic. “Our first priority during this international crisis has been to ensure the he |
|
| April 9, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2020 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Number |
|
| February 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-36591 Otonomy, Inc. ( |
|
| February 27, 2020 |
Description of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934. Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following description summarizes the most important terms of our capital stock as set forth in our amended and restated certificate of incorporation and amended and restated bylaws. This summary does not purport to be complete and is qualified in its entirety |
|
| February 27, 2020 |
S-8 1 d894055ds8.htm S-8 As filed with the Securities and Exchange Commission on February 27, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OTONOMY, INC. (Exact name of registrant as specified in its charter) Delaware 26-2590070 (State or other jurisdiction of incorporation or orga |
|
| February 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2020 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 27, 2020 |
Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update • Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s disease • Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, February 27, 2020 - Otonomy, Inc. (Nasdaq: OT |
|
| February 14, 2020 |
OTIC / Otonomy, Inc. / Weber David Allen - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Otonomy, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 68906L 105 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 4, 2020 |
OTIC / Otonomy, Inc. / FIRST MANHATTAN CO - NONE Passive Investment SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Otonomy Inc. (Name of Issuer) COMMON (Title of Class of Securities) 68906L105 (CUSIP Number) Calendar Year 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| January 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2020 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 9, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Provides Corporate and Product Pipeline Update Three programs with clinical trial results in 2020 including OTIVIDEX™ Phase 3 trial in Ménière’s disease Current capital funds operations into 2021 SAN DIEGO, January 9, 2020 - Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, t |
|
| November 5, 2019 |
OTIC / Otonomy, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36591 Otonomy, Inc. (E |
|
| November 5, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2019 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 5, 2019 |
Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update • Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s disease • Broadest pipeline in neurotology field expanded to include gene therapy collaboration targeting most common cause of congenital hearing loss • Current capital funds |
|
| August 1, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 d732944d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2019 Otonomy, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporatio |
|
| August 1, 2019 |
Sales Agreement, dated as of August 1, 2019, between Otonomy, Inc. and Cowen and Company, LLC. EX-1.1 Exhibit 1.1 OTONOMY, INC. $40,000,000 COMMON STOCK SALES AGREEMENT August 1, 2019 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Otonomy, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agr |
|
| August 1, 2019 |
424B5 1 d782563d424b5.htm 424B5 Table of Contents As filed pursuant to Rule 424(b)(5) Registration No. 333-227269 PROSPECTUS SUPPLEMENT (To prospectus dated September 21, 2018) $40,000,000 Otonomy, Inc. Common Stock We have entered into a certain Common Stock Sales Agreement, or sales agreement, with Cowen and Company, LLC, or Cowen, relating to shares of our common stock offered by this prospectu |
|
| August 1, 2019 |
Otonomy Reports Second Quarter 2019 Financial Results and Provides Corporate Update Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Second Quarter 2019 Financial Results and Provides Corporate Update • Clinical-stage programs on track with results expected from three trials in 2020 • Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. EDT SAN DIEGO, August 1, 2019 - Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the |
|
| August 1, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2019 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36591 Otonomy, Inc. (Exact |
|
| June 14, 2019 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2019 Otonomy, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 6, 2019 |
Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update • OTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020 • OTIPRIOÒ co-promotion agreement completed with Glenmark Therapeutics • OTIVIDEXä Phase 3 trial in Ménière’s disease on track for results in first half of 2020 • OTO-413 Phase 1/2 trial in hear |
|
| May 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 otic-8k20190506.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2019 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporatio |
|
| May 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36591 Otonomy, Inc. (Exact |
|
| April 19, 2019 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 4, 2019 |
Form S-8 As filed with the Securities and Exchange Commission on March 4, 2019 Registration No. |
|
| March 4, 2019 |
Otonomy Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update • OTIVIDEXä Phase 3 trial in Ménière’s disease on track for results in first half 2020 • OTO-313 Phase 1/2 trial in tinnitus expected to start in second quarter of 2019 • OTO-413 Phase 1/2 trial in hearing loss expected to start in third quarter of 2019 • $15 million |
|
| March 4, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 otic-8k20190304.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2019 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporat |
|
| March 4, 2019 |
Now and UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36591 Otonomy |
|
| February 11, 2019 |
OTIC / Otonomy, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* OTONOMY, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68906L105 (CUSIP Number) January 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 11, 2019 |
OTIC / Otonomy, Inc. / FIRST MANHATTAN CO - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Otonomy Inc. (Name of Issuer) COMMON (Title of Class of Securities) 68906L105 (CUSIP Number) Calendar Year 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 8, 2019 |
OTIC / Otonomy, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* OTONOMY, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68906L105 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 3, 2019 |
EX-10.1 Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of December 31, 2018 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collate |
|
| January 3, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2018 Otonomy, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commissio |
|
| January 3, 2019 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Provides Corporate and Product Pipeline Update Three programs with clinical trial results in 2020 including OTIVIDEX™ Phase 3 trial in Ménière’s disease Current capital funds operations into 2021 SAN DIEGO, January 3, 2019 - Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurot |
|
| November 5, 2018 |
EX-99.1 2 otic-ex9918.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Third Quarter 2018 Financial Results and Provides Corporate Update Conference call and webcast today at 4:30 p.m. EST Conference call will include review of OTO-413 program selected as "Hot Topic" at Society for Neuroscience Annual Meeting SAN DIEGO, November 5, 2018 - Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceut |
|
| November 5, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2018 Otonomy, Inc. |
|
| November 5, 2018 |
OTIC / Otonomy, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36591 Otonomy, Inc. (E |
|
| September 19, 2018 |
CORRESP September 19, 2018 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Irene Paik Re: Otonomy, Inc. Registration Statement on Form S-3 File No. 333-227269 Acceleration Request Requested Date: September 21, 2018 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securi |
|
| September 10, 2018 |
EX-4.5 Exhibit 4.5 OTONOMY, INC. TO AS TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.1 Definitions. 1 Section 1.2 Compliance Certificates and Opinions. 9 Section 1.3 Form of Documents Delivered to Trustee. 9 Section 1.4 Acts of Holders; Record Dates. 10 Section 1.5 Notices, etc., |
|
| September 10, 2018 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on September 10, 2018 Registration No. |
|
| September 10, 2018 |
EX-4.3 Exhibit 4.3 OTONOMY, INC. TO AS TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.1 Definitions. 1 Section 1.2 Compliance Certificates and Opinions. 7 Section 1.3 Form of Documents Delivered to Trustee. 8 Section 1.4 Acts of Holders; Record Dates. 9 Section 1.5 Notices, etc., to Trus |
|
| September 10, 2018 |
Statement re Computation of Ratio of Earnings to Fixed Charges EX-12.1 Exhibit 12.1 Otonomy, Inc Statement Regarding the Computation of Ratio of Earnings to Fixed Charges The following table sets forth our ratio of earnings to fixed charges for the six months ended June 30, 2018 and the years ended December 31, 2017, 2016, 2015. As the ratios of earnings to fixed charges indicate less than one-to-one coverage for each of the periods presented, we have provide |
|
| August 8, 2018 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Second Quarter 2018 Financial Results and Provides Corporate Update Conference call and webcast today at 4:30 p.m. EDT SAN DIEGO, August 8, 2018 - Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today reported financial results for the quarter ended June 30, 2018 and pr |
|
| August 8, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2018 Otonomy, Inc. |
|
| August 8, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36591 Otonomy, Inc. (Exact |
|
| June 21, 2018 |
Submission of Matters to a Vote of Security Holders 8-K 1 d598866d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2018 Otonomy, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorpor |
|
| May 9, 2018 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports First Quarter 2018 Financial Results and Provides Corporate Update Conference call and webcast today at 4:30 p.m. EDT SAN DIEGO, May 9, 2018 - Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today reported financial results for the quarter ended March 31, 2018 and provi |
|
| May 9, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 otic-8k20180509.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2018 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporatio |
|
| May 9, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36591 Otonomy, Inc. (Exact |
|
| April 27, 2018 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 8, 2018 |
S-8 As filed with the Securities and Exchange Commission on March 8, 2018 Registration No. |
|
| March 8, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d516406d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2018 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) |
|
| March 8, 2018 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update Type C meeting completed with FDA for OTIVIDEX™ in Ménière’s disease Consistent with prior guidance, pivotal trial for OTIVIDEX to start mid-2018 Conference call and webcast today at 4:30 p.m. EST SAN DIEGO, March 8, 2018 — Otonomy, Inc. (NASDAQ: OTIC), a bio |
|
| March 8, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36591 Otonomy, Inc. ( |
|
| February 9, 2018 |
OTIC / Otonomy, Inc. / FIRST MANHATTAN CO - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Otonomy Inc. (Name of Issuer) COMMON (Title of Class of Securities) 68906L105 (CUSIP Number) Calendar Year 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 8, 2018 |
OTIC / Otonomy, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* OTONOMY, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68906L105 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| January 22, 2018 |
OTIC / Otonomy, Inc. SC TO-I/A SC TO-I/A 1 d528608dsctoia.htm SC TO-I/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OTONOMY, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.001 par value (Title of Class of Securities) 68906L105 (CUS |
|
| January 9, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d520767d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2018 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorp |
|
| January 9, 2018 |
Otonomy Provides Corporate and Product Pipeline Update EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Provides Corporate and Product Pipeline Update SAN DIEGO, January 9, 2018 ? Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for diseases and disorders of the ear, today provided an update on its product pipeline and financial guidance. ? OTIVIDEX? demonstrated statistical significan |
|
| December 22, 2017 |
8-K 1 d460198d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2017 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of inco |
|
| December 20, 2017 |
EX-99.(a)(1)(C) Exhibit (a)(1)(C) OTONOMY, INC. OFFER TO EXCHANGE CERTAIN OUTSTANDING STOCK OPTIONS FOR NEW STOCK OPTIONS ELECTION FORM THE OFFER EXPIRES AT 9:00 P.M., PACIFIC TIME, ON JANUARY 19, 2018, UNLESS THE OFFER IS EXTENDED Terms used in this Election Form, including the Election Terms & Conditions and Election Instructions attached hereto, that are defined in the Offer to Exchange have th |
|
| December 20, 2017 |
EX-99.(a)(1)(B) Exhibit (a)(1)(B) EMAIL TO ALL ELIGIBLE EMPLOYEES From: [email protected] on behalf of David A. Weber, Ph.D., President and Chief Executive Officer, Otonomy, Inc. To: All Eligible Employees Date: December 20, 2017 Subject: LAUNCH OF OTONOMY?S STOCK OPTION EXCHANGE PROGRAM Dear Otonomy Eligible Employee: You are receiving this email because you are eligible to parti |
|
| December 20, 2017 |
EX-99.(a)(1)(E) Exhibit (a)(1)(E) Form of Reminder Email The Otonomy, Inc. (?Otonomy?) offer to exchange certain outstanding stock options for new stock options (referred to as the ?Offer?) currently is still open. Please note that the Offer will expire at 9:00 p.m., Pacific Time, on January 19, 2018, unless we extend the Offer. The Offer deadline will be strictly enforced, so we encourage you to |
|
| December 20, 2017 |
Screenshots from Offer Website. EX-99.(a)(1)(I) Exhibit (a)(1)(I) Login Screen Password change Screen Welcome Screen Make My Election (Step 1 of 4)?FOR OFFICER Breakeven Calculator Make My Election (Step 1 of 4) - FOR NON-OFFICER Review My Election (Step 2 of 4) Submit My Election (Step 3 of 4) Print My Election Confirmation (Step 4 of 4) Print Confirmation |
|
| December 20, 2017 |
Offer to Exchange Certain Outstanding Stock Options for New Stock Options, dated December 20, 2017. EX-99.(a)(1)(A) Table of Contents Exhibit (a)(1)(A) OTONOMY, INC. OFFER TO EXCHANGE CERTAIN OUTSTANDING STOCK OPTIONS FOR NEW STOCK OPTIONS This document constitutes part of the prospectus relating to the securities that have been registered under the Securities Act of 1933, as amended. The prospectus relates to the Otonomy, Inc. Amended and Restated 2010 Equity Incentive Plan and the Otonomy, Inc |
|
| December 20, 2017 |
EX-99.(a)(1)(D) Exhibit (a)(1)(D) Form of Confirmation to Eligible Employees Otonomy, Inc. (?Otonomy?) has received your election via [Otonomy?s Offer website]/[fax] by which you elected to accept or reject Otonomy?s offer to exchange certain outstanding stock options for new stock options (the ?Offer?) with respect to some or all of your outstanding eligible option grants, subject to the terms an |
|
| December 20, 2017 |
EX-99.(a)(1)(G) Exhibit (a)(1)(G) EMAIL TO ALL ELIGIBLE EMPLOYEES From: David A. Weber, Ph.D., President and Chief Executive Officer, Otonomy, Inc. To: All Eligible Employees Date: [DATE] Subject: MEETING RE: OTONOMY?S STOCK OPTION EXCHANGE PROGRAM Dear Otonomy Eligible Employee: You recently received a launch email from [email protected] on my behalf announcing Otonomy, Inc.?s of |
|
| December 20, 2017 |
EX-99.(a)(1)(H) Otonomy?s Stock Option Exchange Program [DATE] CONFIDENTIAL Exhibit (a)(1)(H) Agenda What is the option exchange program (?Offer?)? Why is this Offer being made? What is the time period for the Offer? Who can participate in the Offer? Which options are eligible for exchange? What will you receive in the Offer? What is the vesting schedule of the new options? What?s next / How do I |
|
| December 20, 2017 |
Form of Expiration Notice Email. EX-99.(a)(1)(F) Exhibit (a)(1)(F) Notice to Eligible Employees Regarding Expiration of Offering Period To: Eligible Employees From: [email protected] on behalf of David A. Weber, Ph.D., President and Chief Executive Officer, Otonomy, Inc. Date: [January 19, 2018] Subject: Expiration of Otonomys Stock Option Exchange Program As of [9:00 p.m., Pacific Time, on January 19, 2018], we |
|
| December 20, 2017 |
SC TO-I SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OTONOMY, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.001 par value (Title of Class of Securities) 68906L105 (CUSIP Number of Class of Securities? Underlying Common |
|
| November 27, 2017 |
Otonomy Announces Plan to Focus Resources on Development Programs EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Announces Plan to Focus Resources on Development Programs ? Company to focus resources on completing OTIVIDEX? clinical development to support U.S. regulatory approval for M?ni?re?s disease, and advancing multiple other programs addressing hearing loss and tinnitus ? Discontinuing commercial support of OTIPRIO? which is expected to save more than |
|
| November 27, 2017 |
Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2017 Otonomy, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (Commissio |
|
| November 8, 2017 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update Conference call and webcast today at 4:30 p.m. EST SAN DIEGO, November 8, 2017 ? Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today reported finan |
|
| November 8, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K 1 d491120d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2017 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorpo |
|
| November 8, 2017 |
EX-99.2 Exhibit 99.2 FOR IMMEDIATE RELEASE Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX? in Patients with M?ni?re?s Disease ? Achieved primary endpoint (p value = 0.029) ? Company plans to meet with FDA to discuss results and clinical requirements for registration ? Management will review results during third quarter conference call at 4:30 p.m. EST today SAN DIEGO, Nov |
|
| November 8, 2017 |
OTIC / Otonomy, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36591 Otonomy, Inc. (E |
|
| September 11, 2017 |
OTIC / Otonomy, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment SC 13G/A 1 oton.htm DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment # 4 Name of Issuer: Otonomy, Inc. Title of Class of Securities: Common Stock CUSIP Number: 68906L105 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROUP: (a) N/A ( |
|
| September 8, 2017 |
OTIC / Otonomy, Inc. / FEDERATED INVESTORS INC /PA/ Passive Investment SC 13G/A 1 form.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2*) OTONOMY, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 68906L105 (CUSIP Number) August 31, 2017 (Date of Event Which Requires Fili |
|
| August 30, 2017 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2017 Otonomy, Inc. |
|
| August 30, 2017 |
Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménière’s Disease EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX? in Patients with M?ni?re?s Disease ? Missed primary endpoint (p value = 0.62) and all key vertigo secondary endpoints ? Company to immediately suspend all development activities for OTIVIDEX ? Company is also undertaking a review of its product pipeline plans and commercial efforts in order |
|
| August 3, 2017 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update Conference call and webcast today at 4:30 p.m. EDT SAN DIEGO, August 3, 2017 ? Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today reported financ |
|
| August 3, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d436419d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2017 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) |
|
| August 3, 2017 |
OTIC / Otonomy, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36591 Otonomy, Inc. (Exact |
|
| July 6, 2017 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated July 6, 2017 (the “Schedule 13D”), with respect to the Common Stock of Otonomy, Inc. |
|
| July 6, 2017 |
OTIC / Otonomy, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* OTONOMY, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 68906L105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC Samuel D. Isaly 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Addres |
|
| June 23, 2017 |
Submission of Matters to a Vote of Security Holders 8-K 1 d414599d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2017 Otonomy, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorpor |
|
| May 4, 2017 |
Otonomy 10-Q (Quarterly Report) otic-10q20170331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36591 |
|
| May 4, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d385540d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2017 Otonomy, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36591 26-2590070 (State or other jurisdiction of incorporation) (C |
